4 - ALUMIS INC. (0001847367) (Issuer)

4 - ALUMIS INC. (0001847367) (Issuer)

4 - ALUMIS INC. (0001847367) (Issuer)

4 - ALUMIS INC. (0001847367) (Issuer)

4 - ALUMIS INC. (0001847367) (Issuer)

4 - ALUMIS INC. (0001847367) (Issuer)

4 - ALUMIS INC. (0001847367) (Issuer)

4 - ALUMIS INC. (0001847367) (Issuer)

4 - ALUMIS INC. (0001847367) (Issuer)

4 - ALUMIS INC. (0001847367) (Issuer)

4 - ALUMIS INC. (0001847367) (Issuer)

4 - ALUMIS INC. (0001847367) (Issuer)

4 - ALUMIS INC. (0001847367) (Issuer)

4 - ALUMIS INC. (0001847367) (Issuer)

4 - ALUMIS INC. (0001847367) (Issuer)

4 - ALUMIS INC. (0001847367) (Issuer)

4 - ALUMIS INC. (0001847367) (Issuer)

4 - ALUMIS INC. (0001847367) (Issuer)

4 - ALUMIS INC. (0001847367) (Issuer)

4 - ALUMIS INC. (0001847367) (Issuer)

Wells Fargo initiated coverage of Alumis with a rating of Overweight and set a new price target of $17.00

Guggenheim resumed coverage of Alumis with a rating of Buy and set a new price target of $18.00

Oppenheimer initiated coverage of Alumis with a rating of Outperform and set a new price target of $32.00

Robert W. Baird initiated coverage of Alumis with a rating of Outperform and set a new price target of $25.00

H.C. Wainwright initiated coverage of Alumis with a rating of Buy and set a new price target of $30.00

Cantor Fitzgerald initiated coverage of Alumis with a rating of Overweight

Leerink Partners initiated coverage of Alumis with a rating of Outperform and set a new price target of $29.00

Guggenheim initiated coverage of Alumis with a rating of Buy and set a new price target of $32.00

Morgan Stanley initiated coverage of Alumis with a rating of Overweight and set a new price target of $36.00

8-K - ALUMIS INC. (0001847367) (Filer)

424B5 - ALUMIS INC. (0001847367) (Filer)

424B5 - ALUMIS INC. (0001847367) (Filer)

8-K - ALUMIS INC. (0001847367) (Filer)

8-K - ALUMIS INC. (0001847367) (Filer)

SCHEDULE 13D - ALUMIS INC. (0001847367) (Subject)

SCHEDULE 13D/A - ALUMIS INC. (0001847367) (Subject)

10-Q - ALUMIS INC. (0001847367) (Filer)

8-K - ALUMIS INC. (0001847367) (Filer)

8-K - ALUMIS INC. (0001847367) (Filer)

SOUTH SAN FRANCISCO, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced the closing of its upsized underwritten public offering of 20,297,500 shares of its common stock, including the full exercise of the underwriters' option to purchase an additional 2,647,500 shares, at a price to the public of $17.00 per share. The gross proceeds to Alumis from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $345.1 million. All of the shares in the offering were sold by Alumis

SOUTH SAN FRANCISCO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced the pricing of an upsized underwritten public offering of 17,650,000 shares of its common stock at a price to the public of $17.00 per share. The gross proceeds to Alumis from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $300.0 million. All shares in the offering are being sold by Alumis. The offering is expected to close on January 9, 2026, subject to the satisfaction of cus

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced its plans to commence an underwritten public offering of $175.0 million of shares of its common stock. All of the shares are being offered by Alumis. In addition, Alumis expects to grant the underwriters a 30-day option to purchase up to an additional $26.25 million of shares of its common stock at the public offering price per share. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the p

DENVER, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Markets are opening with a clear appetite for substance over speculation, as investors gravitate toward companies delivering late-stage clinical wins, scalable science, and data-driven precision platforms. Alumis (NASDAQ:ALMS): Phase 3 Data Redefines the Oral Psoriasis Landscape Alumis is firmly in focus after announcing positive topline results from two Phase 3 trials (ONWARD1 and ONWARD2) evaluating envudeucitinib, its next-generation oral TYK2 inhibitor, in moderate-to-severe plaque psoriasis. Both trials met all primary and secondary endpoints with high statistical significance, with efficacy that stands out among oral therapies. By Week 24,

– Both Phase 3 trials met all primary and secondary endpoints with high statistical significance in patients with moderate-to-severe plaque psoriasis – – Approximately 65% of patients achieved PASI 90 and more than 40% achieved PASI 100 at Week 24, on average – – Envudeucitinib demonstrated a favorable safety and tolerability profile consistent with the Phase 2 program – – Alumis plans to submit a New Drug Application to the FDA in the second half of 2026 – – Conference call and webcast scheduled for 8:00 a.m. ET today – SOUTH SAN FRANCISCO, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a late-stage biopharmaceutical company developing next-generation targeted

– Conference Call and Webcast to be held Tuesday, January 6, 2026, at 8:00 a.m. ET – SOUTH SAN FRANCISCO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that the Company will report topline data from the Phase 3 ONWARD clinical program evaluating envudeucitinib in patients with moderate-to-severe plaque psoriasis on Tuesday, January 6, 2026. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m. ET to discuss the results. Conference Call and Webcast DetailsAlumis' conference call and webcast to

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today reported financial results for the quarter ended September 30, 2025, and highlighted recent achievements. "As we continue to advance our pipeline, we are entering an important period for Alumis. Our teams have been working diligently, and we are eagerly anticipating key milestones ahead - with topline Phase 3 ONWARD data for envudeucitinib (envu) in moderate-to-severe plaque psoriasis (PsO) expected to be announced early in the first quarter of 2026, followed by t

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that the Company will participate in the following investor conferences: Guggenheim's 2nd Annual Healthcare Innovation ConferenceNovember 10-12, 2025, Boston, MAFireside chat: Tuesday, November 11, 2025 at 1:30 pm ET Stifel 2025 Healthcare ConferenceNovember 11-13, 2025, New York, NYPresentation: Wednesday, November 12, 2025 at 2:00 pm ET To access the live webcasts please visit the "Events" page of the "Investors" section of the Alumis website. Webcast replays wi

SOUTH SAN FRANCISCO, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that the Company will participate in the following investor conferences: Cantor Global Healthcare Conference 2025 in New York, NY on September 3 at 9:45 am ET (fireside chat);Wells Fargo 2025 Healthcare Conference in Boston, MA on September 5 at 9:30 am ET (fireside chat);Morgan Stanley 23rd Annual Global Healthcare Conference in New York, NY on September 8 at 4:50 pm ET (fireside chat);H.C. Wainwright 27th Annual Global Investment Conference in New York, NY on Sept

–Completed enrollment in Phase 3 ONWARD clinical trials for envudeucitinib in moderate-to-severe plaque psoriasis; topline readout expected in early Q1 2026– –Completed enrollment in Phase 2b LUMUS clinical trial for envudeucitinib in systemic lupus erythematosus (SLE); topline readout expected in Q3 2026– –Completed merger with ACELYRIN, Inc. to strengthen financial position and support advancement of late-stage immunology pipeline– –Cash, cash equivalents and marketable securities of $486.3 million as of June 30, 2025 expected to fund operations into 2027– SOUTH SAN FRANCISCO, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical comp

– Both Phase 3 trials met all primary and secondary endpoints with high statistical significance in patients with moderate-to-severe plaque psoriasis – – Approximately 65% of patients achieved PASI 90 and more than 40% achieved PASI 100 at Week 24, on average – – Envudeucitinib demonstrated a favorable safety and tolerability profile consistent with the Phase 2 program – – Alumis plans to submit a New Drug Application to the FDA in the second half of 2026 – – Conference call and webcast scheduled for 8:00 a.m. ET today – SOUTH SAN FRANCISCO, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a late-stage biopharmaceutical company developing next-generation targeted

– Conference Call and Webcast to be held Tuesday, January 6, 2026, at 8:00 a.m. ET – SOUTH SAN FRANCISCO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that the Company will report topline data from the Phase 3 ONWARD clinical program evaluating envudeucitinib in patients with moderate-to-severe plaque psoriasis on Tuesday, January 6, 2026. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m. ET to discuss the results. Conference Call and Webcast DetailsAlumis' conference call and webcast to

Topline data from Phase 3 ONWARD trials for Alumis' ESK-001 in moderate-to-severe plaque psoriasis on track for readout in first half of 2026; Topline data from Phase 2b LUMUS trial in systemic lupus erythematosus on track for readout in 2026 Evaluation underway of development plan for ACELYRIN's lonigutamab to confirm differentiation in a capital efficient manner Pro forma cash position of approximately $737 million as of December 31, 2024, provides runway into 2027, beyond expected multiple clinical readouts for highly differentiated late-stage portfolio Alumis and ACELYRIN stockholders to own ~55% and ~45%, respectively, of combined company on a fully diluted basis Combined company wi

SC 13D - ALUMIS INC. (0001847367) (Subject)

SC 13G - ALUMIS INC. (0001847367) (Subject)

SC 13D - ALUMIS INC. (0001847367) (Subject)

SC 13D - ALUMIS INC. (0001847367) (Subject)